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The gastrointestinal (GI) tract is the largest producer of serotonin (5-hydroxytryptamine (5-HT)) in the body, and as such it is
intimately connected with GI function and physiology. 5-HT produced by enterochromafﬁn (EC) cells is an important enteric
mucosal signaling molecule and has been implicated in a number of GI diseases, including inﬂammatory bowel disease and
functionaldisorderssuchasirritablebowelsyndrome.Thisreviewwillfocusonwhatisknownofbasic5-HTphysiologyandalso
on the emerging evidence for its novel role in activation of immune response and inﬂammation in the gut. Utilizing pubmed.gov,
search terms such as ‘‘5-HT,’’ ‘‘EC cell,’’ and ‘‘colitis,’’ as well as pertinent reviews, were used to develop a brief overview of EC
cell biology and the association between 5-HT and various GI disorders. It is the aim of this review to provide the readers with an
update on EC cell biology and current understanding on the role of 5-HT in GI disorders speciﬁcally in inﬂammatory conditions.
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INTRODUCTION
The discovery of 5-hydroxytryptamine (5-HT) was accom-
plished by two independent research endeavors, one search-
ing for vasoconstrictors causing hypertension described a
molecule called serotonin, the other characterizing the
granules found in intestinal enterochromafﬁn (EC) cells
described a molecule called enteroamine.
1,2 5-HT is a well-
known neurotransmitter of the central nervous system and
traditionally it is known to inﬂuence a range of behavioral,
physiological, and cognitive functions. However, most of the
5-HT in the body is synthesized from EC cells in the
gastrointestinal (GI) tract and is an important mediator in
normal gut physiology. Abnormal regulation of 5-HT (Table 1)
in the human gut has been implicated with a diverse array of
GI disorders, such as inﬂammatory bowel disease (IBD),
3,4
and functional disorders such as irritable bowel syndrome
(IBS).
3,5,6 In addition, alteration in 5-HT signaling is shown to
be associated with celiac disease,
7 colorectal cancer,
8,9 and
diverticular disease.
10 Despite this association with a variety
of GI disorders it is not clear how the changes in 5-HT occur,
what role 5-HT has in intestinal pathophysiology, and whether
by modulating 5-HT production and signaling is it possible to
elicit a therapeutic effect.
EC CELLS AND 5-HT
The association between altered EC cells numbers, 5-HT
production, and GI diseases highly emphasizes the signiﬁ-
cance of 5-HT in intestinal pathophysiology. Understanding
EC cell biology, mechanisms of 5-HT production, and the
precise roles of EC cells/5-HT in intestinal pathology may ulti-
mately lead to improved therapeutic strategies in GI disorders.
Origin and differentiation of EC cells. The GI tract
contains the largest endocrine organ in the body; how-
ever, in contrast with other endocrine organs the various
types of enteroendocrine cells are scattered throughout
the intestinal tract. Enteroendocrine cells are responsible
for releasing various biologically active compounds such
as gastrin, secretin, stomatostatin, cholecystokinin, chromo-
granins, and 5-HT.
11 The best-characterized subset of
enteroendocrine cells are EC cells and are found
throughout the gut.
12 EC cells are found at the base of the
crypts in the GI tract, where they originate from stem cells
also located near the base of the crypt.
13 The turnover of EC
cells is considerably slower, EC cells last 15–150 days in
comparison with enterocytes, which last 2–4 days in rats.
14
There are potentially two distinguishable pools of stem cells
within the intestinal crypt from which EC cells could
originate.
15 The regulators of intestinal cell lineage and
maintenance of the intestinal stem cell niche seems to be
the Notch, Wnt, and bone morphogenetic protein signaling
pathways.
16–18 Lateral inhibition of Notch signaling down
regulates cellular expression of Hes-1, the key transcription
factor for the enterocyte cell lineage.
19 This allows endo-
crinecellsinparticulartobegintoexpresstranscriptionfactors
such as Math 1 and neurogenin 3, which direct a more
secretory cell lineage.
20–23 The necessity of neurogenin 3 in
the development of EC cells has been demonstrated in
neurogenin 3
 /  mice, which develop without any endocrine
cells.
20
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www.nature.com/ctg5-HT synthesis and release. Synthesis of 5-HT by
intestinal EC cells begins with the conversion of dietary
tryptophan to 5-hydroxy-L-tryptophan, which is catalyzed by
tryptophan hydroxylase (TpH). Recent studies have
identiﬁed two isoforms of the TpH enzyme, TpH1, which is
present in mainly peripheral organs such as the gut, and
TpH2, which is associated with the nervous system and
present predominantly in the brain stem.
24,25 The second
step catalyzed by L-amino acid decarboxylase, which is also
present in EC cells, converts 5-hydroxy-L-tryptophan to
5-HT.
26 The 5-HT is then packaged into granules by
vesicular monoamine transporter 1 at both the apical and
basal ends of the EC cell, just below the surface of the
plasma membrane.
27,28 Degradation of 5-HT is facilitated by
monoamine oxidase A that drives the conversion of 5-HT into
5-hydrosyindoleacetic acid (5-HIAA).
The release of 5-HT from EC cells follows intraluminal
distension,vagal-nerve stimulation, ingestionof a meal, orthe
presence of acid, amino acids, or hypo- or hyper-osmotic
solutionsintheduodenum.Microvillipresentontheapicalend
oftheECcell projectintothelumen andfunctionassensorsof
luminal content, turning the physiochemical signals of the
lumen into biochemical endocrine signals.
28 The released
5-HT from EC cells either enters the lumen or lamina propria
where it can act upon enterocytes or cells of the enteric
nervous system and initiate secretion and enteric pulsation
patterns.
28,29 Cholera toxin has been shown to release 5-HT
intothehumanjejunum
30thisisrelevantforboththesmalland
large intestine. Short-chain fatty acids, produced by bacteria
in the colon, can also stimulate 5-HT release.
29 The diet may
also inﬂuence 5-HT release, D-glucose, and D-galactose, but
not fructose induced the release of 5-HT from human BON
cells.
31 The complex interaction of the microbiota, diet, and
the cells of the intestine all have an inﬂuence on 5-HT
synthesis, release, and degradation, and therefore all may be
responsible for the altered 5-HT function seen in many
GI diseases.
Turnover of EC cells and the release of 5-HT can be altered
by signaling molecules released by surrounding cells. Cells
associated with the immune, neural, and vascular system are
in close proximity to EC cells.
32,33 Our work using Trichuris
muris infection in severe combined immunodeﬁciency mice
exempliﬁes the role of CD4þ T cells in modulating the EC cell
number and 5-HT content.
34 Wild-type mice (BLK6/C57)
infected with T. muris produce a predominantly Th2 immune
response, and this same study found the interleukin-13
receptor on murine EC cells, which solidiﬁes the role of Th2
cytokines in EC cell biology.
34 The close proximity of immune
cells with EC cells and the ability of 5-HT and cytokines
to regulate the function of both the immune and endo-
crine system are suggestive that this interaction governs
many of the pathophysiological aspects associated with
GI disease.
Role of 5-HT in immune activation and inﬂammation. We
have previously shown how the immune system can
inﬂuence 5-HT-expressing EC cell biology, however, in turn
5-HT can also inﬂuence the immune system (Figure 1).
34–37
There are many serotonergenic receptors that have been
found on various immune cells such as B and T lymphocytes,
monocytes, macrophage, and dentritic cells.
38 In addition,
mast cells, macrophage, and T cells also have the ability to
synthesis 5-HT from tryptophan.
39–41 5-HT is also a chemo-
tactic molecule for eosinophils, dendritic cells, and mast
cells.
42–44 Previous studies have described 5-HT receptors
on human monocyte-derived dendritic cells; immature den-
dritic cells primarily expressed 5-HT1B, 5-HT1E, and 5-HT2B
receptors, whereas mature dendritic cells express 5-HT4 and
5-HT7 receptors.
45 This shift in the expression of 5-HT
receptors may help to explain the differential functions of
5-HT, for instance 5-HT can function as a chemotactic
molecule in immature but not lipopolysaccharides-matured
dendritic cells.
42 We have found that dendritic cells isolated
from mice with decreased ability to synthesize 5-HT (TPH1
 / )
in the intestine produced less interleukin-12p70 but cytokine
production could be restored by adding 5-HT.
46
In the experimental models of colitis induced by trinitro-
benzene sulfonic acid, dinitrobenzenesulfonic acid, and
dextran sodium sulfate, an increase in 5-HT content has been
observed.
47,48 Studies from our laboratory recently reported
reduced severity of colitis in TPH1
 /  mice as compared with
wild-type mice after dextran sodium sulfate- and dinitroben-
zenesulfonic acid-colitis.
35 Restoration of 5-HT in TPH1
 / 
mice by administration of a 5-HT precursor (5-hydroxy-
L-tryptophan) enhanced the severity of colitis. These ﬁndings
are supported by studies from other groups, which have
shown that chemical-induced colitis or spontaneous colitis
associated with interleukin-10 deﬁciency is increased in
severity when coupled with the 5-HT-enhancing effects of
the knockout of 5-HT reuptake transporter (SERT).
49,50 In
clinical studies, in patients with diarrhea-predominant IBS
duodenal immune activation is associated with reduced levels
of SERT mRNA in platelets.
51 Taken together, these studies
suggest an important role of 5-HT in the pathogenesis of GI
disease by inﬂuencing pro-inﬂammatory mediator production
and immune modulation.
5-HT IN GI DISORDERS
5-HT and pathophysiology of GI diseases. The role of
5-HT in the pathophysiology of GI diseases can vary, among
the most important roles of 5-HT is its inﬂuence on the
motility of the GI tract and its ability to modulate the immune
system. Extensive reviews on receptors for 5-HT (Table 2),
Table 1 Studies of EC cell numbers and 5-HT synthesis in IBD and IBS
GI disorders EC cells 5-HT TpH mRNA Reference
CD Increased Increased Kidd et al.
77
CD Increased Minderhoud et al.
78
UC Decreased Decreased Coates et al.
3
CD and UC Decreased Magro et al.
4
CD and UC Increased El-Salhy et al.
60
UC Decreased Ahonen et al.
62
IBS Increased Ahonen et al.
62
IBS Unchanged Decreased Coates et al.
3
IBS-C Increased Miwa et al.
5
Abbreviations:CD,Crohn’sdisease;EC,enterochromafﬁn;GI,gastrointestinal;
IBD, inﬂammatory bowel disease; IBS, irritable bowel syndrome; TpH,
tryptophan hydroxylase; UC, ulcerative colitis; 5-HT, 5-hydroxytryptamine.
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Clinical and Translational Gastroenterologysuch as 5-HT3 and 4, have been developed outlining the
pivotal role of 5-HT in both altered motility and sensation
of nausea and pain commonly associated with GI dis-
orders.
13,52,53 Alosetron (5-HT3 receptor antagonist) became
the ﬁrst agent approved by the US Food and Drug Adminis-
tration for the treatment of diarrhea-predominant IBS.
However, the drug unexpectedly was associated with
ischemic colitis and, rarely, with severe constipation-induced
complications.
54 The case of alosetron prompts a rethinking of
our approaches to the pharmacological modulation of
serotoninergic pathways and warrants more studies on 5-HT
in the context of intestinal pathology and pathophysiology.
The pathophysiology of GI diseases is also associated with
aberrant immune responses, such as lymphocyte inﬁltration
and hyperplasia, resulting in inﬂammation of the enteric
mucosa. 5-HT receptors have been found on cells associated
with the immune system and has been shown in vitro to
affect the proliferation of lymphocytes and recruitment of
T-cells.
55,56 The inﬂuence of 5-HT on immune cell function
may have a critical role in the pathogenesis of various
GI diseases as a signiﬁcant reduction of colonic 5-HT was
associated with decreased inﬂammation in two different
animal models of colitis.
35 Furthermore, the expression of
cytokine receptors on 5-HT-expressing EC cells supports the
Figure 1 Modulation of EC cell biology by immune cells and modulation of immune cells by 5-HT in GI disease. The role of 5-HT in modulating the innate and adaptive
immune system can vary by cell type. 5-HT has been shown to enhance phagocytosis in murine macrophages.
40 In addition, 5-HT can increase chemotaxis of dendritic cells
and promote the release of the Th2-attracting chemokine CCL22 while decreasing the Th1 chemokine CXCL10.
42 Finally 5-HT has a proliferative effect on CD4þ T cells,
whichwhencoupledwith5-HTeffectondendriticcellscreateamorepermissiveenvironmentforaTh2immuneresponse.CD4þ Tcells
50particularlyTh2cytokines,suchas
interleukin-13,
49 in turn may inﬂuence on EC cell biology, 5-HT synthesis, and 5-HT release.
Table 2 Clinical utility of agonists and antagonists associated with 5-HT metabolism in gastrointestinal disorders
Target Mechanism Potential and documented clinical utility
5-HT1 receptor family Agonist FD; IBS-D
Antagonist FD; IBS; GERD
5-HT2 receptor family Agonist None
Antagonist IBS-D (women only)
5-HT3 receptor Agonist GERD; constipation-predominant IBS
Antagonist IBS-D; FD; nocturnal GERD; chemotherapy-induced nausea and vomiting;
radiation induced nausea and vomiting; post-operative vomiting
5-HT4 receptor Agonist Chronic constipation; gastroparesis; GERD; IBS-C; IBS-M; FD
Antagonist GERD
5-HT7 receptor Agonist No known applications in GI disorders, however, receptor is thought to
mediate colonic relaxation, therefore a potential role in functional GI disorders
Antagonist
Abbreviations: FD, functional dyspepsia; GI, gastrointestinal; IBS-C, constipation-predominant irritable bowel syndrome; IBS-M, mixed IBS; GERD,
gastroesophageal reﬂux disease; IBS-D, diarrhea-predominant IBS; 5-HT, 5-hydroxytryptamine.
Table adapted from references 58,79–86 as well as company websites and FDA.gov.
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Clinical and Translational Gastroenterologyexistence of an immuno–endocrine axis in the context of
various GI disorders.
34
5-HT in GI disease translational medicine. Understanding
5-HT signaling in GI disorders is very important not only
because of the alteration in 5-HT response observed in
various GI diseases but also in light of serious and unfore-
seen complications caused from the use of 5-HT receptor
antagonist in clinical practice (Table 2). The location of 5-HT-
expressing EC cells within the epithelial mucosa of the GI
tract is perfect for the delivery of an oral administered small
molecule modulator of 5-HT synthesis. Recent clinical trials
using a small molecule inhibitor of TpH1 have shown
the ability to alleviate the symptoms associated with IBS,
especially diarrhea predominate IBS. Treatment with TpH1
inhibitor decreased blood 5-HT level, relieved pain/dis-
comfort, and increased stool consistency.
57,58 Modulation
of tryptophan metabolism, especially 5-HT synthesis may be
a novel target for developing therapies for GI disorders.
Modulation of the 5-HT signaling pathway in GI disease has
been extensively investigated; however, adverse side effects
have restricted the use of many 5-HT receptor targeted
drugs.
13,52,53,59 Drugs released speciﬁcally at the site of
inﬂammation could decrease collateral damage by requiring a
lesser amount of drug. For example, addition of covalently
linked hydrophilic carriers would enhance the retention of the
pro-drug within the GI tract until it reached a speciﬁc site.
At this point, speciﬁc enzymes from the intestinal cells or
microﬂora could cleave the compound allowing its absorption
by the intestine.
60
5-HT and IBD. IBD includes two chronic GI diseases,
ulcerative colitis and Crohn’s disease, which are relapsing
inﬂammatory conditions of unknown etiology. Inﬂammation of
the intestinal mucosa has been found to affect 5-HT signaling
in both humans and animal models.
4,35,61,62 Changes in EC
cell numbers and in 5-HT content have been reported in
association with both Crohn’s disease and ulcerative
colitis.
61,63–65 Approximately 50% of patients with IBD in
long-standing remission have IBS-like symptoms, which may
be related to these inﬂammation-induced alterations in EC
cells and 5-HT signaling.
66 It is also shown that consumption
of selective 5-HT reuptake inhibitors is associated with
microscopic colitis.
67 Increases in 5-HT content have also
been observed in experimental models of colitis.
47,48 In our
opinion, the intersection between 5-HT-expressing EC cells
(5-HT itself) and the immune responses that drive IBD are
paramount to the pathogenesis of this disease.
5-HT and IBS. IBS is associated with abdominal pain and
cramping, as well as changes in the functionality of the
bowel. It is a disorder of dichotomous extremes, with many
patients experiencing predominantly constipation, diarrhea,
or both. Diarrhea-predominant IBS is associated with
elevated 5-HT whereas constipation-predominant IBS is
associated with decreased levels of 5-HT in the colon
mucosa.
13,52 Alterations in gut motility are paramount to
this disorder and contribute to prevalence of both diarrhea
and constipation. The etiology of IBS is unclear, however,
alterations in 5-HT metabolism have been suggested to
contribute to the pathophysiology of this disease.
68
There are several studies both in humans and in experi-
mental models that have reported associations of symptoms
of IBS and: the number of EC cells, the presence of 5-HT,
mRNA levels of TpH, and the expression of SERT in mucosal
biopsies.
3,5,69,70 In addition, a recent study examining the
microbiota of patients who self-reported the severity of IBS, it
has been found that the severity was associated with the
presence of a Ruminococcus torques-like (94% similarity in
16S rRNA gene sequence) phylotype.
71 It is reasonable to
assume that the microﬂora can also inﬂuence the function of
5-HT, potentially modulating its content, and signaling in the
intestinal mucosa resulting in GI disease.
5-HT and celiac disease. Celiac disease is caused by an
immune reaction to gliadin, a prolamin (gluten protein) found
in wheat, and is associated with chronic diarrhea and fatigue.
Small intestine crypt hyperplasia and an increase in the
number of 5-HT-expressing EC cells is also associated with
Celiac disease.
72,73 With more EC cells there is also
increased 5-HT content in the duodenal mucosa of in both
adults and children.
74 A recent study by Coleman et al.
7
evaluated both fasting and postprandial plasma 5-HT levels
in patients after a high-carbohydrate meal. Celiac patients
had increased 5-HT-containing EC cell numbers as well as
signiﬁcantly higher peak plasma 5-HT levels.
7 These obser-
vations point to altered EC cell biology, increased 5-HT
release, and impaired 5-HT uptake resulting in altered
5-HT metabolism. This disease promotes a predominantly
Th1 cytokine environment, therefore elevated levels of both
tumor necrosis factor-a and interferon-g can decrease the
expression of SERT and reduce 5-HT uptake by cells in
the intestine.
75 Further studies are required to understand
the precise role of 5-HT in the pathogenesis of celiac
disease.
5-HT and diverticulitis. Although diverticulosis is a
common afﬂiction in the western society, there is very little
known about its pathogenesis. Altered mobility is an
important aspect of the disease, which suggests that alter
5-HT signaling and metabolism may be as well. Diverticulitis
develops from diverticulosis, which is the formation of
pouches (diverticular) on the outside of the inﬂamed colon.
In a recent study, asymptomatic diverticulosis patients as
well as patients with a history of acute diverticulitis were
compared with healthy controls.
10 The only difference
observed in the study was that patients with a history of
acute diverticulitis exhibited decreased expression of 5-HT
transporter (SERT) expression.
10 The requirement of an
inﬂammatory event seems to be associated with a change in
5-HT signaling further emphasizing the intimate relationship
between 5-HT metabolism and inﬂammation. Further studies
such as this would be useful to understand the mechanisms
involved in the development and progression of this disease.
CONCLUDING REMARKS
The regulation of 5-HT- and 5-HT-expressing EC cells is
intimately associated with the inﬂammatory processes that
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Clinical and Translational GastroenterologydrivemanyGI disorders.RecentstudiesonECcellsand5-HT
have generated a number of concepts that provide insight into
howtheimmuneandendocrinesystemsofthegutinterface.It
is evident from these studies that mediators from immune
cells such as cytokines have an important role in EC cell
biology and production of 5-HT in the gut. In addition, 5-HT
has a key role in the pathogenesis of experimental colitis and
in generation of pro-inﬂammatory mediators from immune
cells. If this is not complex enough, this entire relationship is
occurring in the presence of varying diets and mediators
secreted by the microbiota, which may directly or indirectly
inﬂuence the EC cell function.
Recently, Margolis et al.
75 has shown that inhibition of 5-HT
synthesis using a speciﬁc inhibitor of the TpH1 enzyme
reduces the severity of trinitrobenzene sulfonic acid-induced
colitis in mice. This ﬁnding furthers supports our observation
that 5-HT is a critical molecule in pathogenesis of colitis and
suggest that targeted inhibition of 5-HT synthesis may
ultimately help in the development of improved therapeutic
strategies in GI inﬂammatory disorders.
5-HT exerts a wide range of effects in the gut, largely due to
thepresence ofmultiplereceptorsubtypesthatarepresenton
smooth muscle, enteric neurons, enterocytes, and immune
cells. Agonist or antagonist for various 5-HT receptor is used
in a variety of GI disorders, which include IBS, functional
dyspepsia, and chronic constipation (Table 2). The 5-HT7
receptor, coupled to Gs proteins and stimulating cAMP
production, is the most recently identiﬁed member of the
family of 5-HT receptors. Our lab has evaluated the 5-HT7
receptor antagonist (SB-269970) and found that disruption of
5-HT7 receptor signaling signiﬁcantly reduces the severity of
both dextran sodium sulfate and dinitrobenzenesulfonic acid-
induced colitis in mice.
76 Pharmaco-modulation of 5-HT
signaling using speciﬁc agonists and antagonists represents
one of the best strategies for alleviating many of the
symptoms associated with GI disease; however, the effect
on the immune system should also be considered.
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